Facebook's Huge Crowd Pleaser

Related Link: 

The social-networking giant defies law of large numbers, showing benefits of scale.

Amgen Profit Rises 13%, 2016 Outlook Raised

Related Link: 

Amgen Inc. said its second-quarter earnings rose 13% on better-than-expected revenue growth, which was again driven by sales of key drugs such as Enbrel.

Teva, Allergan Get FTC Approval for Generics Purchase

Related Link: 

Teva Pharmaceutical Industries Ltd. on Wednesday won regulatory approval from the Federal Trade Commission for its acquisition of Allergan PLC’s generics business, conditioned upon Teva’s divestiture of 75 drugs to rivals.

Gawker Founder Wins Temporary Reprieve From Judgment

Related Link: 

A Florida appeals court temporarily lifted the threat of personal bankruptcy hanging over Gawker Media founder Nick Denton as a result of a heated legal battle with former wrestler Hulk Hogan.

U.S. Durable Goods Orders Tumble 4.0% on Overseas Turmoil

Related Link: 

Demand for long-lasting factory goods fell sharply in June, a sign overseas turmoil is weighing on U.S. manufacturers.

Alere Faces Criminal Probe Over Medicare, Medicaid Billing

Related Link: 

Federal investigators are seeking information about government-billing practices at Alere, adding to a litany of woes at the diagnostic-testing company, as it seeks to complete a deal to sell itself.

Facebook Profit, Revenue Jump as Advertisers Flock to Social Network

Related Link: 

Facebook once again reported growing profit on the strength of its mobile-advertising business, sending its shares higher in after-hours trading.

Google Marches to Its Own Beat

Related Link: 

Alphabet shares appear to be underappreciated ahead of second-quarter earnings.

The Real Lesson of Yahoo's Fall

Related Link: 

Google and Facebook could learn the importance of focus from Yahoo, AOL and their ilk: Don’t try to be everything to everyone by copying, buying or mimicking the latest rival for users’ attention.

How the Fed Could Surprise

Related Link: 

The Federal Reserve’s caution on rates could fade quicker than investors think.

Syndicate content